CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Planned sale Chief Medical Officer sold 22,458 shares at an average $24.49 ($549,928)
- 4 Open-market sale COFO and Secretary sold 2,272 shares at $22.89 ($52,006)
- 4 Open-market sale Chief Medical Officer sold 2,337 shares at $22.89 ($53,494)
- 4 Planned sale Director sold 30,688 shares at an average $22.11 ($678,660)
- 4 Planned sale Director sold 3,080 shares at an average $22.14 ($68,204)
- 4 Planned sale Director sold 1,458 shares at $21.73 ($31,682)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Planned sale Director sold 1,674 shares at $20.39 ($34,133)
- 4 Planned sale Director sold 1,666 shares at $18.29 ($30,471)
- 4 Planned sale Director sold 92,500 shares at $20.50 ($1,896,250)
- 4 Gift President and CEO gave 40,000 shares (gift)
- 4 Planned sale Director sold 1,666 shares at $20.10 ($33,487)
Page 4 of 22 · 436 filings